ClinicalTrials.gg
CompletedNCT05020184Updated Sep 4, 2026Results posted

Effect of Oral Cimetidine in the Protoporphyrias

A Phase 2 interventional study of Cimetidine and Placebo in Erythropoietic Protoporphyria and X-linked Protoporphyria, sponsored by Amy K. Dickey, M.D.. Completed at 3 sites in United States. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Amy K. Dickey, M.D. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
15 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Protoporphyria, Erythropoietic with a site in United States — 4 open to participants now, 4 under way, 2 of them phase 3. Protoporphyria, Erythropoietic · United States.

Enrollment
10th of 13
26 · median 77
Started
2022
with 1 other
Phase 2
5 of 18
none open now
Registered
10th of 18
by date
Lead sponsor
1 of 18
Amy K. Dickey, M.D.

Among the 18 studies in Protoporphyria, Erythropoietic with a site in United States, this one is the 10th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2022, is one of 5 in phase 2, and was the 10th registered.

Protoporphyria, Erythropoietic

29 studies on the registry are indexed under Protoporphyria, Erythropoietic; 5 are open to participants now.

Browse Protoporphyria, Erythropoietic studies →

Open to participants now

4 of the 18 studies in Protoporphyria, Erythropoietic with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Protoporphyria, Erythropoietic studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 3 take children under 18; none take healthy volunteers.

This study: 15 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Protoporphyria, Erythropoietic with a site in United States, or all of them as a file.
02

Study summary

Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) result from genetic defects of heme biosynthesis that cause life-long, painful cutaneous sensitivity to light. The objective of this study is to determine the efficacy and safety of oral cimetidine administration for treatment of the protoporphyrias. Efficacy will be based on protoporphyrin levels, photosensitivity, and quality of life questionnaires.

Funding Source- FDA OOPD

Read the detailed description

Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) are genetic defects of heme biosynthesis that cause life-long, painful cutaneous sensitivity to light. EPP and XLP, collectively called the protoporphyrias, result in the accumulation of the light-sensitive molecule protoporphyrin IX initially in the bone marrow during hemoglobin synthesis and secondarily in erythrocytes, plasma, and the liver. In addition to photosensitivity, protoporphyria can also result in anemia, gallstones, and liver failure. No therapy has been demonstrated to reduce protoporphyrin levels or prevent the potentially life-threatening complications of EPP. Cimetidine has gained attention as a possible treatment for human porphyrias because of a potential off-target effect of inhibition of delta-aminolevulinate synthase (ALAS), the first enzyme of heme biosynthesis. This inhibition was first described in vitro; however, case reports of benefit in EPP have been anecdotal and uncontrolled. Therefore, the objective of this study is to determine the efficacy and safety of oral cimetidine administration in the protoporphyrias. Efficacy will be based on protoporphyrin levels, photosensitivity, and quality of life questionnaires. If the results are positive, this would be the first study providing quality evidence for an agent acting as a disease-modifying therapy for EPP. The study is also attractive because it repurposes an already approved drug with few side effects to treat a rare human disease.

The study design is a prospective, blinded, randomized, 2x2 cross-over design comparing cimetidine to placebo in patients with protoporphyria. Eligible protoporphyria patients will be randomized with equal allocation to one of two treatment sequences that will be administered over two 3-month study periods. Randomization will be stratified by site and permuted block randomization will be used to prevent chronological bias. Patients randomized to sequence 1 will receive placebo during period 1 and cimetidine during period 2. Patients randomized to sequence 2 will receive cimetidine during period 1 and placebo during period 2. Between periods, to eliminate any carry-over effects from the treatment administered in period 1, a wash-out period of 3 months will occur in which all patients receive neither cimetidine nor placebo. Three months was selected for each study period and for the wash-out period because of the rapid decline in protoporphyrin in red cells over the lifespan of the red cell (120 days), as well as to account for the time frame needed to measure light sensitivity in EPP.

03

Conditions studied

  • Erythropoietic Protoporphyria
  • X-linked Protoporphyria

Keywords

  • Erythropoietic Protoporphyria
  • X-linked Protoporphyria
  • EPP
  • Cimetidine
  • Photosensitivity
04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Prior enrollment or co-enrollment in the Longitudinal Study of the Porphyrias (PC Study 7201) with a confirmed diagnosis of EPP or XLP
  • Male or female age ≥15 years at screening
  • Characteristic history of non-blistering cutaneous photosensitivity
  • Willing and capable of giving and following procedures described in the protocol

Exclusion criteria

Exclusion Criteria:

  • Participants not willing to expose themselves to light to the point of prodromal symptoms at least weekly
  • History of liver or bone marrow transplant or liver dysfunction as determined by the Investigator
  • Known or suspected allergy or intolerance to cimetidine
  • Use of any other experimental therapy in the past 3 months at screening
  • Use of cimetidine within the past 3 months at screening
  • Individuals with elevations of porphyrins in plasma or erythrocytes due to other diseases (i.e., secondary porphyrinemia) such as liver and bone marrow diseases
  • Patients with any clinically significant comorbid conditions, which in the opinion of the Investigator, precludes participation
  • Treatment with any drugs or supplements (Appendix 1) that in the opinion of the Investigator can interfere with subject safety or the objectives of the study
  • The participant either does not have a smartphone or is not willing to use his/her smartphone for the study
  • Women who are pregnant, breastfeeding, or actively planning to become pregnant
  • Individuals with moderate to severe renal insufficiency
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
26 participants (actual)

Study arms

  • Active comparator
    Cimetidine

    Cimetidine 800mg orally twice daily

    Drug: Cimetidine

  • Placebo comparator
    Placebo

    Placebo capsule orally twice daily

    Drug: Placebo

Interventions

  • Oral Cimetidine 800mg twice daily.

    Also known as: Tagament

  • DrugPlacebo

    Placebo twice daily

06

What researchers measure

Primary outcomes

  1. Percent Change in Erythrocyte Total Protoporphyrin Level

    Percent change in erythrocyte total protoporphyrin levels after treatment period versus before.

    Time frame: Before and after each 3-month treatment period

Secondary outcomes

  1. Time to Prodrome

    Mean daily self-reported outdoor time, in minutes, before EPP/XLP prodrome onset during the last two months of each treatment period, including days without symptoms.

    Time frame: Last 2 months of each treatment period

  2. Change in PROMIS-57 v2 Domain T-scores From Pre-treatment to End of Each 3-month Treatment Period

    PROMIS-57 v2 assesses 7 health domains: Physical Function, Anxiety, Depression, Fatigue, Sleep Disturbance, Ability to Participate in Social Roles and Activities, and Pain Interference. Domain scores are converted to standardized T-scores with a U.S. general population mean of 50 and standard deviation of 10. Higher scores indicate worse outcomes for Anxiety, Depression, Fatigue, Sleep Disturbance, and Pain Interference, and better outcomes for Physical Function and Ability to Participate in Social Roles and Activities. PROMIS-57 v2 was administered immediately before and at the end of each 3-month treatment period. End-of-period PROMIS-57 v2 domain T-scores were analyzed using mixed-effects linear models adjusted for the immediately pre-treatment PROMIS-57 v2 domain T-score for that treatment period, with treatment as a fixed effect and participant as a random effect. Reported values represent least squared means for change in T-score for the cimetidine and placebo treatment periods.

    Time frame: Immediately before and at the end of the 3-month cimetidine treatment period, and immediately before and at the end of the 3-month placebo treatment period

  3. Change in PROMIS-57 v2 Pain Intensity Scores From Pre-treatment to End of Each 3-month Treatment Period

    PROMIS-57 v2 Pain Intensity is a single item scored from 0 to 10, with higher scores indicating worse pain intensity. The instrument-defined possible score range is 0 to 10. This question was administered immediately before and at the end of each 3-month treatment period in this crossover trial. End-of-period PROMIS-57 v2 Pain Intensity scores were analyzed using mixed-effects linear models adjusted for the immediately pre-treatment Pain Intensity score for that treatment period, with treatment as a fixed effect and participant as a random effect. Reported values represent least squared means for change in Pain Intensity scores for the cimetidine and placebo treatment periods.

    Time frame: Immediately before and at the end of the 3-month cimetidine treatment period, and immediately before and at the end of the 3-month placebo treatment period

  4. Number of Phototoxic Reactions Per Participant During the Last 2 Months of Each Treatment Period

    For each participant, the number of phototoxic reactions during the last 2 months of each 3-month treatment period was recorded. In this crossover trial, the reported outcome compares the number of phototoxic reactions per patient during cimetidine with the number during placebo.

    Time frame: Last 2 months of the 3-month cimetidine treatment period and last 2 months of the 3-month placebo treatment period

  5. Blue Light Dose

    Average daily outdoor blue light dose before EPP/XLP prodrome onset during the last two months of each treatment period, including days without symptoms. Dose data for the day were excluded if the patient did not wear the dosimeter for the entire day.

    Time frame: Last 2 months of each treatment period

07

Results

Posted Jun 29, 2026

Participant flow

A total of 26 patients signed the consent form and were therefore considered enrolled. 25 patients were assigned a randomization group.

Treatment Period 1 (3 months)
Participant flow — Treatment Period 1 (3 months)
MilestonePlacebo/ CimetidineCimetidine/ Placebo
Started1213
Completed1111
Not completed12
Washout period (3 months)
Participant flow — Washout period (3 months)
MilestonePlacebo/ CimetidineCimetidine/ Placebo
Started1111
Completed1111
Not completed00
Treatment Period 2 (3 months)
Participant flow — Treatment Period 2 (3 months)
MilestonePlacebo/ CimetidineCimetidine/ Placebo
Started1111
Completed1111
Not completed00

Outcome measures

PrimaryPercent Change in Erythrocyte Total Protoporphyrin Level

Percent change in erythrocyte total protoporphyrin levels after treatment period versus before.

Time frame:
Before and after each 3-month treatment period
Reported as:
Mean · Percent change
Percent Change in Erythrocyte Total Protoporphyrin Level
Percent changePlaceboCimetidine
Percent Change in Erythrocyte Total Protoporphyrin Level5.24 (-6.93 to 17.40)10.19 (-4.26 to 24.64)
Statistical analysis
  • Placebo vs Cimetidine · Paired t-test · p = 0.59
SecondaryTime to Prodrome

Mean daily self-reported outdoor time, in minutes, before EPP/XLP prodrome onset during the last two months of each treatment period, including days without symptoms.

Time frame:
Last 2 months of each treatment period
Reported as:
Mean · Minutes per day
Time to Prodrome
Minutes per dayPlaceboCimetidine
Time to Prodrome93.89 (72.33 to 115.45)107.21 (85.07 to 129.34)
Statistical analysis
  • Placebo vs Cimetidine · Paired t-test · p = 0.07
SecondaryChange in PROMIS-57 v2 Domain T-scores From Pre-treatment to End of Each 3-month Treatment Period

PROMIS-57 v2 assesses 7 health domains: Physical Function, Anxiety, Depression, Fatigue, Sleep Disturbance, Ability to Participate in Social Roles and Activities, and Pain Interference. Domain scores are converted to standardized T-scores with a U.S. general population mean of 50 and standard deviation of 10. Higher scores indicate worse outcomes for Anxiety, Depression, Fatigue, Sleep Disturbance, and Pain Interference, and better outcomes for Physical Function and Ability to Participate in Social Roles and Activities. PROMIS-57 v2 was administered immediately before and at the end of each 3-month treatment period. End-of-period PROMIS-57 v2 domain T-scores were analyzed using mixed-effects linear models adjusted for the immediately pre-treatment PROMIS-57 v2 domain T-score for that treatment period, with treatment as a fixed effect and participant as a random effect. Reported values represent least squared means for change in T-score for the cimetidine and placebo treatment periods.

Time frame:
Immediately before and at the end of the 3-month cimetidine treatment period, and immediately before and at the end of the 3-month placebo treatment period
Reported as:
Least squares mean · T-score change
Change in PROMIS-57 v2 Domain T-scores From Pre-treatment to End of Each 3-month Treatment Period
T-score changePlaceboCimetidine
PROMIS-57 Fatigue Score Change-1.46 ± 1.93100.61 ± 1.9310
PROMIS-57 Anxiety Score Change-2.61 ± 1.65-1.33 ± 1.65
PROMIS-57 Ability to Participate in Social Roles and Activities Score Change3.41 ± 2.025.55 ± 2.02
PROMIS-57 Sleep Disturbance Score Change0.06 ± 1.310.8 ± 1.31
PROMIS-57 Physical Function Score Change0.70 ± 1.602.33 ± 1.60
PROMIS-57 Pain Interference Score Change0.64 ± 1.63-3.56 ± 1.63
PROMIS-57 Depression Score Change-0.28 (-2.68 to 2.12)1.81 (-0.59 to 4.21)
Statistical analysis
  • Placebo vs Cimetidine · Mixed-effects linear model · p = 0.23Mixed-effects linear model of end-of-period PROMIS-57 v2 domain T-score, adjusted for the immediately pre-treatment domain T-score for that treatment
  • Placebo vs Cimetidine · Mixed-effects linear model · p = 0.58Mixed-effects linear model of end-of-period PROMIS-57 v2 domain T-score, adjusted for the immediately pre-treatment domain T-score for that treatment
  • Placebo vs Cimetidine · Mixed-effects linear model · p = 0.36Mixed-effects linear model of end-of-period PROMIS-57 v2 domain T-score, adjusted for the immediately pre-treatment domain T-score for that treatment
  • Placebo vs Cimetidine · Mixed-effects linear model · p = 0.92Mixed-effects linear model of end-of-period PROMIS-57 v2 domain T-score, adjusted for the immediately pre-treatment domain T-score for that treatment
  • Placebo vs Cimetidine · Mixed-effects linear model · p = 0.28 (PROMIS-57 v2 Physical Function domain T-scores are standardized to the U.S. general population (mean 50, SD 10). Higher scores indicate better physical function. The instrument-defined possible T-score range for this domain is 20.9 to 59.7.)Mixed-effects linear model of end-of-period PROMIS-57 v2 domain T-score, adjusted for the immediately pre-treatment domain T-score for that treatment
  • Placebo vs Cimetidine · Mixed-effects linear model · p = 0.36Mixed-effects linear model of end-of-period PROMIS-57 v2 domain T-score, adjusted for the immediately pre-treatment domain T-score for that treatment
  • Placebo vs Cimetidine · Mixed-effects linear model · p = 0.17Mixed-effects linear model of end-of-period PROMIS-57 v2 domain T-score, adjusted for the immediately pre-treatment domain T-score for that treatment
SecondaryChange in PROMIS-57 v2 Pain Intensity Scores From Pre-treatment to End of Each 3-month Treatment Period

PROMIS-57 v2 Pain Intensity is a single item scored from 0 to 10, with higher scores indicating worse pain intensity. The instrument-defined possible score range is 0 to 10. This question was administered immediately before and at the end of each 3-month treatment period in this crossover trial. End-of-period PROMIS-57 v2 Pain Intensity scores were analyzed using mixed-effects linear models adjusted for the immediately pre-treatment Pain Intensity score for that treatment period, with treatment as a fixed effect and participant as a random effect. Reported values represent least squared means for change in Pain Intensity scores for the cimetidine and placebo treatment periods.

Time frame:
Immediately before and at the end of the 3-month cimetidine treatment period, and immediately before and at the end of the 3-month placebo treatment period
Reported as:
Least squares mean · Score on a scale change
Change in PROMIS-57 v2 Pain Intensity Scores From Pre-treatment to End of Each 3-month Treatment Period
Score on a scale changePlaceboCimetidine
Change in PROMIS-57 v2 Pain Intensity Scores From Pre-treatment to End of Each 3-month Treatment Period-0.27 (-1.19 to 0.64)-1.27 (-2.19 to -0.36)
Statistical analysis
  • Placebo vs Cimetidine · Mixed-effects linear model · p = 0.31Mixed model of end-of-period Pain Intensity score adjusted for immediately pre-treatment score, with treatment fixed and participant random.
SecondaryNumber of Phototoxic Reactions Per Participant During the Last 2 Months of Each Treatment Period

For each participant, the number of phototoxic reactions during the last 2 months of each 3-month treatment period was recorded. In this crossover trial, the reported outcome compares the number of phototoxic reactions per patient during cimetidine with the number during placebo.

Time frame:
Last 2 months of the 3-month cimetidine treatment period and last 2 months of the 3-month placebo treatment period
Reported as:
Geometric mean · phototoxic episodes per patient
Number of Phototoxic Reactions Per Participant During the Last 2 Months of Each Treatment Period
phototoxic episodes per patientCimetidinePlacebo
Number of Phototoxic Reactions Per Participant During the Last 2 Months of Each Treatment Period2.0 ± 1.61.8 ± 2.1
Statistical analysis
  • Cimetidine vs Placebo · Poisson regression model with log link · p = 0.92
SecondaryBlue Light Dose

Average daily outdoor blue light dose before EPP/XLP prodrome onset during the last two months of each treatment period, including days without symptoms. Dose data for the day were excluded if the patient did not wear the dosimeter for the entire day.

Time frame:
Last 2 months of each treatment period
Reported as:
Mean · mJ/cm^2/day
Blue Light Dose
mJ/cm^2/dayPlaceboCimetidine
Blue Light Dose6063.10 (4017.57 to 8108.64)5985.22 (3502.59 to 8467.85)
Statistical analysis
  • Placebo vs Cimetidine · Paired t-test · p = 0.94

Adverse events

Collected over Throughout the duration of the study; the study duration was approximately 9.5 months per participant. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cimetidine0/24 (0%)1/24 (4.2%)14/24 (58.3%)
Placebo0/23 (0%)1/23 (4.3%)7/23 (30.4%)
Washout Period0/22 (0%)0/22 (0%)3/22 (13.6%)
Most frequent serious events
Most frequent serious events
EventCimetidinePlaceboWashout Period
Urinary tract infectionRenal and urinary disorders0/241/230/22
DiverticulitisGastrointestinal disorders1/240/230/22
Most frequent other events
Most frequent other events
EventCimetidinePlaceboWashout Period
Upper respiratory infectionRespiratory, thoracic and mediastinal disorders8/242/231/22
HeadacheNervous system disorders2/243/231/22
DiarrheaGastrointestinal disorders3/240/230/22
TransaminitisHepatobiliary disorders0/242/230/22
NauseaNervous system disorders2/241/231/22
HeartburnGastrointestinal disorders2/241/230/22

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Placebo/ CimetidineCimetidine/ PlaceboTotal
Mean44.8 ± 19.453.2 ± 13.649.1 ± 16.9
Sex: Female, Male
Sex: Female, Male(Participants)Placebo/ CimetidineCimetidine/ PlaceboTotal
Female6713
Male6612
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo/ CimetidineCimetidine/ PlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White121325
More than one race000
Unknown or Not Reported000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo/ CimetidineCimetidine/ PlaceboTotal
Hispanic or Latino033
Not Hispanic or Latino121022
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Placebo/ CimetidineCimetidine/ PlaceboTotal
United States121325
Study Site
Study Site(Participants)Placebo/ CimetidineCimetidine/ PlaceboTotal
MGH121224
UTMB011
08

Study locations

3 sites
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Atrium Health Wake Forest Baptist Medical Center
    Winston-Salem, North Carolina 27157, United States
  • University of Texas Medical Branch
    Galveston, Texas 77555, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in the published article, as well as the study protocol and statistical analysis plan, may be shared, after de-identification (text, tables, figures, and appendices), if meeting the time frame and access criteria listed below.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 9 months and ending 36 months following article publication

Access criteria: With whom: Researchers who provide a methodologically sound proposal that is approved by the study investigators For what type of analysis: To achieve the aims of the approved proposal. By what mechanisms will the data be available: Proposals should be directed to adickey@mgh.harvard.edu . To gain access, data requestors will need to sign a data access agreement.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Apr 2025, 34 months.

Results were first posted in Jun 2026, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2021
First posted
Aug 25, 2021
StartActual
Jun 14, 2022
Primary completionActual
Apr 24, 2025
CompletionActual
Apr 24, 2025
Results first posted
Jun 29, 2026
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05020184
Lead sponsor
Amy K. Dickey, M.D.
Responsible party
Amy K. Dickey, M.D. (Instructor of Medicine, Massachusetts General Hospital) — Sponsor-investigator
First posted
Aug 25, 2021
Start date
Jun 14, 2022
Primary completion
Apr 24, 2025
Completion
Apr 24, 2025
Results posted
Jun 29, 2026
Last update
Sep 4, 2026

Study contacts

Amy K Dickey, MD
principal investigator · Massachusetts General Hospital
Karl Anderson, MD
principal investigator · University of Texas

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cimetidine

Start the discussion